Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

BACKGROUND: While novel drugs have been developed, docetaxel remains one of the standard initial systemic therapies for castration-resistant prostate cancer (CRPC) patients. Despite the excellent anti-tumor effect of docetaxel, its severe adverse effects sometimes distress patients. Therefore, it wo...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Urol
Главные авторы: Yamashita, Shimpei, Kohjimoto, Yasuo, Iguchi, Takashi, Koike, Hiroyuki, Kusumoto, Hiroki, Iba, Akinori, Kikkawa, Kazuro, Kodama, Yoshiki, Matsumura, Nagahide, Hara, Isao
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2016
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4802623/
https://ncbi.nlm.nih.gov/pubmed/27001073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-016-0133-y
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы